Perspectives on window of opportunity trials in head and neck cancer: lessons from the EORTC 90111-24111-NOCI-HNCG study

Sandra Schmitz, Carmela Caballero, Laura D Locati

Research output: Contribution to journalArticle

Abstract

Assessing tumour response using a traditional phase I, II and III trial approach is not without limitations, particularly when targeted therapies are involved. Window of opportunity trials, performed presurgically but differing from neoadjuvant studies, were developed in an attempt to overcome the limitations of the traditional approach. A recent window of opportunity trial, the EORTC 90111-24111-NOCI-HNCG study, evaluated afatinib in treatment-naive patients with squamous cell carcinoma of the head and neck. While this study was the first to demonstrate the activity of afatinib in this setting and to define its potential predictive biomarkers, it also highlighted the challenges associated with the window of opportunity trial design, including the impact of patient selection, tumour site, and other organisational issues. This report details the key learnings from the EORTC 90111-24111-NOCI-HNCG study and provides recommendations to overcome the challenges of this particular trial design.

Original languageEnglish
Pages (from-to)219-223
Number of pages5
JournalEuropean Journal of Cancer
Volume104
DOIs
Publication statusPublished - Nov 2018

Fingerprint

Head and Neck Neoplasms
Patient Selection
Neoplasms
Biomarkers
Learning
Therapeutics
BIBW 2992
Carcinoma, squamous cell of head and neck

Cite this

Perspectives on window of opportunity trials in head and neck cancer : lessons from the EORTC 90111-24111-NOCI-HNCG study. / Schmitz, Sandra; Caballero, Carmela; Locati, Laura D.

In: European Journal of Cancer, Vol. 104, 11.2018, p. 219-223.

Research output: Contribution to journalArticle

@article{9197172e26c34c20a0b27b5f35f26374,
title = "Perspectives on window of opportunity trials in head and neck cancer: lessons from the EORTC 90111-24111-NOCI-HNCG study",
abstract = "Assessing tumour response using a traditional phase I, II and III trial approach is not without limitations, particularly when targeted therapies are involved. Window of opportunity trials, performed presurgically but differing from neoadjuvant studies, were developed in an attempt to overcome the limitations of the traditional approach. A recent window of opportunity trial, the EORTC 90111-24111-NOCI-HNCG study, evaluated afatinib in treatment-naive patients with squamous cell carcinoma of the head and neck. While this study was the first to demonstrate the activity of afatinib in this setting and to define its potential predictive biomarkers, it also highlighted the challenges associated with the window of opportunity trial design, including the impact of patient selection, tumour site, and other organisational issues. This report details the key learnings from the EORTC 90111-24111-NOCI-HNCG study and provides recommendations to overcome the challenges of this particular trial design.",
author = "Sandra Schmitz and Carmela Caballero and Locati, {Laura D}",
note = "Copyright {\circledC} 2018 Elsevier Ltd. All rights reserved.",
year = "2018",
month = "11",
doi = "10.1016/j.ejca.2018.07.315",
language = "English",
volume = "104",
pages = "219--223",
journal = "European Journal of Cancer",
issn = "0959-8049",
publisher = "Elsevier Ltd",

}

TY - JOUR

T1 - Perspectives on window of opportunity trials in head and neck cancer

T2 - lessons from the EORTC 90111-24111-NOCI-HNCG study

AU - Schmitz, Sandra

AU - Caballero, Carmela

AU - Locati, Laura D

N1 - Copyright © 2018 Elsevier Ltd. All rights reserved.

PY - 2018/11

Y1 - 2018/11

N2 - Assessing tumour response using a traditional phase I, II and III trial approach is not without limitations, particularly when targeted therapies are involved. Window of opportunity trials, performed presurgically but differing from neoadjuvant studies, were developed in an attempt to overcome the limitations of the traditional approach. A recent window of opportunity trial, the EORTC 90111-24111-NOCI-HNCG study, evaluated afatinib in treatment-naive patients with squamous cell carcinoma of the head and neck. While this study was the first to demonstrate the activity of afatinib in this setting and to define its potential predictive biomarkers, it also highlighted the challenges associated with the window of opportunity trial design, including the impact of patient selection, tumour site, and other organisational issues. This report details the key learnings from the EORTC 90111-24111-NOCI-HNCG study and provides recommendations to overcome the challenges of this particular trial design.

AB - Assessing tumour response using a traditional phase I, II and III trial approach is not without limitations, particularly when targeted therapies are involved. Window of opportunity trials, performed presurgically but differing from neoadjuvant studies, were developed in an attempt to overcome the limitations of the traditional approach. A recent window of opportunity trial, the EORTC 90111-24111-NOCI-HNCG study, evaluated afatinib in treatment-naive patients with squamous cell carcinoma of the head and neck. While this study was the first to demonstrate the activity of afatinib in this setting and to define its potential predictive biomarkers, it also highlighted the challenges associated with the window of opportunity trial design, including the impact of patient selection, tumour site, and other organisational issues. This report details the key learnings from the EORTC 90111-24111-NOCI-HNCG study and provides recommendations to overcome the challenges of this particular trial design.

U2 - 10.1016/j.ejca.2018.07.315

DO - 10.1016/j.ejca.2018.07.315

M3 - Article

C2 - 30301582

VL - 104

SP - 219

EP - 223

JO - European Journal of Cancer

JF - European Journal of Cancer

SN - 0959-8049

ER -